The CR rate and total mortality rate were 35.3% (6/17) and 47.1% (8/17) in APL with STAT5B-RARa, in contrast to 95% and 5% in APL with PML-RARa, respectively (Table 1 ). This evidence concerns the gene PML and acute promyelocytic leukemia.